Citigroup Initiates Coverage On Intuit with Buy Rating, Announces Price Target of $538
Citigroup analyst Steven Enders initiates coverage on Intuit (NASDAQ:INTU) with a Buy rating and announces Price Target of $538.
Citigroup Initiates Coverage On Workiva with Buy Rating, Announces Price Target of $86
Citigroup analyst Steven Enders initiates coverage on Workiva (NYSE:WK) with a Buy rating and announces Price Target of $86.
Citigroup Initiates Coverage On Asana with Neutral Rating, Announces Price Target of $23
Citigroup analyst Steven Enders initiates coverage on Asana (NYSE:ASAN) with a Neutral rating and announces Price Target of $23.
Raymond James Initiates Coverage On Midland States Bancorp with Market Perform Rating
Raymond James analyst Daniel Tamayo initiates coverage on Midland States Bancorp (NASDAQ:MSBI) with a Market Perform rating.
Raymond James Initiates Coverage On AnaptysBio with Outperform Rating, Announces Price Target of $35
Raymond James analyst Steven Seedhouse initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Outperform rating and announces Price Target of $35.
Citigroup Initiates Coverage On Monday.Com with Buy Rating, Announces Price Target of $156
Citigroup analyst Steven Enders initiates coverage on Monday.Com (NASDAQ:MNDY) with a Buy rating and announces Price Target of $156.
CORRECTION: Jefferies Initiates Coverage On CTI BioPharma with Buy Rating, Announces Price Target of $13 – Correct Analyst Firm Updated
CORRECTION:Jefferies analyst Kelly Shi initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Buy rating and announces Price Target of $13, correct Analyst Firm updated.
JMP Securities Initiates Coverage On Aviat Networks with Market Outperform Rating, Announces Price Target of $50
JMP Securities analyst Erik Suppiger initiates coverage on Aviat Networks (NASDAQ:AVNW) with a Market Outperform rating and announces Price Target of $50.
Citigroup Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $70
Citigroup analyst David Lebowitz initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Buy rating and announces Price Target of $70.
Citigroup Initiates Coverage On Pliant Therapeutics with Buy Rating, Announces Price Target of $36
Citigroup analyst David Lebowitz initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Buy rating and announces Price Target of $36.